News

Chemtex builds biorefinery
Enlarge image

BusinessDenmarkItaly

Chemtex builds biorefinery

24.08.2012 - The US government will support Novozymes's partner Chemtex Inc. in its aim to construct a cellulosic ethanol plant in North Carolina by backing a US$99m loan.

The plant is expected to be located in Sampson County, North Carolina and produce 20 million gallons (76 million liters) of bioethanol per year from up to 600,000 tons of non-food grasses. The enzymes necessary for processing the biomass will be provided by Danish biotech company Novozymes (Baegsvaard). The construction is set to begin in late 2012. “Realising a commercial scale cellulosic ethanol plant in the United States and proving that it can produce cost competitive sustainable ethanol is an important milestone in the commercialisation process of advanced biofuels,” said Guido Ghisolfi, President of the Chemtex Group, which is a unit of the Italian chemical company Grupo Mossi & Ghisolfi.http://www.gruppomg.com/history.php?mi=201 

Slated to open in 2014, the plant will employ approximately 65 employees and indirectly generate 250 more jobs in the community, not including construction jobs. The feedstock will be grown on low productivity/marginal land that is in part being utilised as “spray fields” for the hog farming industry. Wilmington, North Carolina-based Chemtex received US$3.9m from the US Department of Agriculture in Junehttp://www.chemtex.com/templates/news_20120613.html to grow more than 4,000 acres of miscanthus and switchgrass, which will now be used as feedstock. Chemtex and Novozymes have already started a collaboration this April aimed at building the world’s first industrial plant for fermentation of second generation bioethanol from cheap straw feeds.

http://www.european-biotechnology-news.com/news/news/2012-03/chemtex-builds-biorefinery.html

PoliticsFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

FinancingAustriaUKSwitzerlandGermany

08.04.2015 To bring its lead product of a new class of antimicrobials to phase 3 trials, Nabriva Therapeutics has completed a US$120m Series B financing.

Research & DevelopmentNetherlands

07.04.2015 Gene therapy is attracting more and more big pharma companies. Now, Bristol-Myers Squibb has forged a US$1bn collaboration with Dutch uniQure, also picking up a 4.9% share in the company.

Stock MarketsFrance

02.04.2015 Sensorion is the latest French biotech to go public, following a spate of IPOs on Paris Euronext. The biopharma plans for a €12m IPO to finance its pipeline of inner ear disease drugs.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX4.84 EUR34.82%
  • FORMYCON31.25 EUR11.61%
  • PAION2.76 EUR6.98%

FLOP

  • MEDIGENE12.41 EUR-3.42%
  • SANTHERA96.75 CHF-2.12%
  • MOLOGEN5.01 EUR-1.18%

TOP

  • WILEX4.84 EUR63.5%
  • FORMYCON31.25 EUR35.0%
  • CO.DON3.35 EUR29.8%

FLOP

  • CYTOS1.08 CHF-22.9%
  • BIOTEST78.40 EUR-18.9%
  • THERAMETRICS0.07 CHF-12.5%

TOP

  • SANTHERA96.75 CHF2368.1%
  • CYTOS1.08 CHF671.4%
  • WILEX4.84 EUR469.4%

FLOP

  • MOLOGEN5.01 EUR-55.5%
  • BIOFRONTERA2.40 EUR-26.8%
  • THERAMETRICS0.07 CHF-22.2%

No liability assumed, Date: 27.04.2015